Age-related behavioural phenotype and cellular characterisation of mice with progressive ablation of D1 dopamine receptor-expressing cells

Behavioural Brain Research

Volumn 206, Issue 1, 2010, Pages 78-87

  Babovic, Daniela ^b   Jiang, Luning ^a   Gantois, Ilse ^a   Lawrence, Andrew J ^a   Ferreri, Vincenzo ^a   Schütz, Günter ^c   Waddington, John L ^b   Drago, John ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

D1 dopamine receptor; Huntington's disease; Neurodegeneration; Targeted cell deletion

Indexed keywords

DOPAMINE 1 RECEPTOR;

ADAPTATION; ADULT ANIMAL; AGE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BEHAVIOR; BRAIN NERVE CELL; CELL LOSS; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; EXTRAPYRAMIDAL SYNDROME; FEMALE; HABITUATION; HYPERACTIVITY; LIGHT DARK CYCLE; MALE; MASTICATION; MAZE TEST; MOUSE; MOUSE MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; UPREGULATION; WORKING MEMORY;

AGE FACTORS; ANIMALS; ATROPHY; AUTORADIOGRAPHY; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GAIT; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR SKILLS; NEURONS; NUCLEUS ACCUMBENS; PHENOTYPE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; ROTAROD PERFORMANCE TEST; SOCIAL BEHAVIOR;

EID: 70350185418     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.08.036     Document Type: Article

References (53)

1. Albin R.L., Reiner A., Anderson K.D., Dure L.S.t., Handelin B., Balfour R., et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 31 (1992) 425-430
2. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 12 (1989) 366-375
3. Andrews T.C., Weeks R.A., Turjanski N., Gunn R.N., Watkins L.H., Sahakian B., et al. Huntington's disease progression. PET and clinical observations. Brain 122 Pt 12 (1999) 2353-2363
4. Augood S.J., Faull R.L., Love D.R., and Emson P.C. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 72 (1996) 1023-1036
5. Babovic D., O'Tuathaigh C.M., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., et al. Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice. Behav Brain Res 183 (2007) 236-239
6. Backman L., Robins-Wahlin T.B., Lundin A., Ginovart N., and Farde L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 120 Pt 12 (1997) 2207-2217
7. Bhidayasiri R., and Truong D.D. Chorea and related disorders. Postgrad Med J 80 (2004) 527-534
8. Bourin M., and Hascoet M. The mouse light/dark box test. Eur J Pharmacol 463 (2003) 55-65
9. Casanova E., Fehsenfeld S., Mantamadiotis T., Lemberger T., Greiner E., Stewart A.F., et al. A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis 31 (2001) 37-42
10. Clifford J.J., Drago J., Natoli A.L., Wong J.Y., Kinsella A., Waddington J.L., et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 109 (2002) 81-88
11. Clifford J.J., Kinsella A., Tighe O., Rubinstein M., Grandy D.K., Low M.J., et al. Comparative, topographically-based evaluation of behavioural phenotype and specification of D(1)-like:D(2) interactions in a line of incipient congenic mice with D(2) dopamine receptor 'knockout'. Neuropsychopharmacology 25 (2001) 527-536
12. Clifford J.J., Tighe O., Croke D.T., Kinsella A., Sibley D.R., Drago J., et al. Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience 93 (1999) 1483-1489
13. Clifford J.J., Tighe O., Croke D.T., Sibley D.R., Drago J., and Waddington J.L. Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology 37 (1998) 1595-1602
14. Clifford J.J., Usiello A., Vallone D., Kinsella A., Borrelli E., and Waddington J.L. Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of the D2 dopamine receptor. Neuropharmacology 39 (2000) 382-390
15. Clinton L.K., Billings L.M., Green K.N., Caccamo A., Ngo J., Oddo S., et al. Age-dependent sexual dimorphism in cognition and stress response in the 3× Tg-AD mice. Neurobiol Dis 28 (2007) 76-82
16. Contarino A., Dellu F., Koob G.F., Smith G.W., Lee K.F., Vale W., et al. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res 835 (1999) 1-9
17. Craufurd D., Thompson J.C., and Snowden J.S. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 14 (2001) 219-226
18. Dellu F., Contarino A., Simon H., Koob G.F., and Gold L.H. Genetic differences in response to novelty and spatial memory using a two-trial recognition task in mice. Neurobiol Learn Mem 73 (2000) 31-48
19. Deng Y.P., Albin R.L., Penney J.B., Young A.B., Anderson K.D., and Reiner A. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat 27 (2004) 143-164
20. Djouma E., and Lawrence A.J. The effect of chronic ethanol consumption and withdrawal on mu-opioid and dopamine D(1) and D(2) receptor density in Fawn-Hooded rat brain. J Pharmacol Exp Ther 302 (2002) 551-559
21. Drago J., Padungchaichot P., Wong J.Y., Lawrence A.J., McManus J.F., Sumarsono S.H., et al. Targeted expression of a toxin gene to D1 dopamine receptor neurons by cre-mediated site-specific recombination. J Neurosci 18 (1998) 9845-9857
22. Faull R.L., Waldvogel H.J., Nicholson L.F., and Synek B.J. The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat. Prog Brain Res 99 (1993) 105-123
23. Gantois I., Fang K., Jiang L., Babovic D., Lawrence A.J., Ferreri V., et al. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. Proc Natl Acad Sci USA 104 (2007) 4182-4187
24. Hiramatsu M., Hoshino T., and Kanematsu K. Pharmacological characterization of the ameliorating effect on short-term memory impairment and antinociceptive effect of KT-90 in mice. Behav Brain Res 160 (2005) 374-381
25. Ho A.K., Sahakian B.J., Brown R.G., Barker R.A., Hodges J.R., Ane M.N., et al. Profile of cognitive progression in early Huntington's disease. Neurology 61 (2003) 1702-1706
26. Hughes R.N. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev 28 (2004) 497-505
27. Kirkwood S.C., Siemers E., Hodes M.E., Conneally P.M., Christian J.C., and Foroud T. Subtle changes among presymptomatic carriers of the Huntington's disease gene. J Neurol Neurosurg Psychiatry 69 (2000) 773-779
28. Lalonde R. The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 26 (2002) 91-104
29. Lamirault L., and Simon H. Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors. Neuropharmacology 41 (2001) 844-853
30. Lawrence A.J., Krstew E., and Jarrott B. Functional dopamine D2 receptors on rat vagal afferent neurones. Br J Pharmacol 114 (1995) 1329-1334
31. Lemiere J., Decruyenaere M., Evers-Kiebooms G., Vandenbussche E., and Dom R. Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year. Acta Neurol Scand 106 (2002) 131-141
32. Marshall J., White K., Weaver M., Flury Wetherill L., Hui S., Stout J.C., et al. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol 64 (2007) 116-121
33. McNamara F.N., Clifford J.J., Tighe O., Kinsella A., Drago J., Croke D.T., et al. Congenic D1A dopamine receptor mutants: ethologically based resolution of behavioural topography indicates genetic background as a determinant of knockout phenotype. Neuropsychopharmacology 28 (2003) 86-99
34. McNamara F.N., Clifford J.J., Tighe O., Kinsella A., Drago J., Fuchs S., et al. Phenotypic, ethologically based resolution of spontaneous and D(2)-like vs D(1)-like agonist-induced behavioural topography in mice with congenic D(3) dopamine receptor "knockout". Synapse 46 (2002) 19-31
35. Montoya A., Pelletier M., Menear M., Duplessis E., Richer F., and Lepage M. Episodic memory impairment in Huntington's disease: a meta-analysis. Neuropsychologia 44 (2006) 1984-1994
36. Montoya A., Price B.H., Menear M., and Lepage M. Brain imaging and cognitive dysfunctions in Huntington's disease. J Psychiatry Neurosci 31 (2006) 21-29
37. Morton A.J., Nicholson L.F., and Faull R.L. Compartmental loss of NADPH diaphorase in the neuropil of the human striatum in Huntington's disease. Neuroscience 53 (1993) 159-168
38. Nance M.A. Huntington disease: clinical, genetic, and social aspects. J Geriatr Psychiatry Neurol 11 (1998) 61-70
39. O'Sullivan G.J., Kinsella A., Grandy D.K., Tighe O., Croke D.T., and Waddington J.L. Ethological resolution of behavioral topography and D2-like vs. D1-like agonist responses in congenic D4 dopamine receptor "knockouts": identification of D4:D1-like interactions. Synapse 59 (2006) 107-118
40. O'Sullivan G.J., Kinsella A., Sibley D.R., Tighe O., Croke D.T., and Waddington J.L. Ethological resolution of behavioural topography and D1-like versus D2-like agonist responses in congenic D5 dopamine receptor mutants: identification of D5:D2-like interactions. Synapse 55 (2005) 201-211
41. O'Tuathaigh C.M., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 147 (2007) 18-27
42. O'Tuathaigh C.M., O'Sullivan G.J., Kinsella A., Harvey R.P., Tighe O., Croke D.T., et al. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. Neuroreport 17 (2006) 79-83
43. Pang T.Y., Du X., Zajac M.S., Howard M.L., and Hannan A.J. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum Mol Genet 18 (2009) 753-766
44. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126 (2003) 1127-1135
45. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., and Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 85 (1988) 5733-5737
46. Ross S.A., Wong J.Y., Clifford J.J., Kinsella A., Massalas J.S., Horne M.K., et al. Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J Neurosci 20 (2000) 6431-6441
47. Sapp E., Ge P., Aizawa H., Bird E., Penney J., Young A.B., et al. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience 64 (1995) 397-404
48. Teper Y., Whyte D., Cahir E., Lester H.A., Grady S.R., Marks M.J., et al. Nicotine-induced dystonic arousal complex in a mouse line harboring a human autosomal-dominant nocturnal frontal lobe epilepsy mutation. J Neurosci 27 (2007) 10128-10142
49. Tippett L.J., Waldvogel H.J., Thomas S.J., Hogg V.M., van Roon-Mom W., Synek B.J., et al. Striosomes and mood dysfunction in Huntington's disease. Brain 130 (2007) 206-221
50. van Duijn E., Kingma E.M., and van der Mast R.C. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 19 (2007) 441-448
51. Waddington J.L., O'Tuathaigh C., O'Sullivan G., Tomiyama K., Koshikawa N., and Croke D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology 181 (2005) 611-638
52. Wall P.M., and Messier C. Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory. Psychopharmacology (Berlin) 160 (2002) 233-244
53. Xu M., Moratalla R., Gold L.H., Hiroi N., Koob G.F., Graybiel A.M., et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79 (1994) 729-742